Yeji

$CRSP

CRISPR Therapeutics AG

Runway:6+ yrs
NasdaqMarket cap: —CIK 0001674416

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD
$CRSPCRISPR Therapeutics AG
exagamglogene autotemcel · severe sickle cell disease (SCD)
“FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia”

Drug pipeline

exagamglogene autotemcel
severe sickle cell disease (SCD)
CTX130
Renal Cell Carcinoma
Non Interventional
Hematologic Malignancy
VCTX210A unit
Diabetes Mellitus
CTX131
Clear Cell Renal Cell Carcinoma
CTX120
Multiple Myeloma
CTX112
SLE (Systemic Lupus)
CTX110
B-cell Malignancy
CTX310
Cardiovascular
VCTX211
Diabetes Mellitus

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06208878Non Interventional—Enrolling By Invitation2038-08-01
NCT07549698CTX112Phase 2Not Yet Recruiting2033-12-01
NCT06925542CTX112Phase 1Recruiting2031-12-31
NCT05643742CTX112Phase 2Recruiting2030-01-01
NCT07491172CTX310Phase 1Recruiting2027-06-01
NCT06492304CTX131Phase 2Completed2026-03-11
NCT05795595CTX131Phase 2Completed2025-09-18
NCT05565248VCTX211Phase 1Terminated2025-08-08
NCT04438083CTX130Phase 1Terminated2024-10-08
NCT04035434CTX110Phase 2Terminated2024-10-04
NCT04502446CTX130Phase 1Terminated2024-08-30
NCT04244656CTX120Phase 1Terminated2024-01-04
NCT05210530VCTX210A unitPhase 1Completed2023-01-19

Recent catalysts

PDUFAMar 30, 2024· 798d ago
$CRSPCRISPR Therapeutics AG
exagamglogene autotemcel · severe sickle cell disease (SCD)
“PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT”
PDUFADec 8, 2023· 911d ago· unknown
$CRSPCRISPR Therapeutics AG
exagamglogene autotemcel · severe sickle cell disease (SCD)
“The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act target action dates of December 8, 2023 and March 30, 2024, respectively.”
NDA/BLA filedJun 8, 2023· 1094d ago· unknown
$CRSPCRISPR Therapeutics AG
exagamglogene autotemcel · severe sickle cell disease (SCD)
“On June 8, 2023, the Company and Vertex announced that the FDA has accepted the BLAs for the product candidate, exa-cel, being investigated for the treatment of SCD and TDT in patients ages 12 to 35.”